Key Highlights
- Shares closed at $2.88 at last closing, up 5.88%, in penny-stock territory.
- Second-quarter 2026 Revenue was about $41.6 million, up roughly 9%, with its Greenbrook treatment-center Business contributing the majority.
- The net loss narrowed sharply to about $3.4 million, and the company posted a first positive adjusted EBITDA of around $0.3 million, with gross Margin expanding to about 51%.
- Cash stood at roughly $25 million against guided Negative cash flow for the year, making the cash runway a key caveat to the turnaround.
Penny stock Neuronetics (NASDAQ:STIM) is a commercial-stage medical-technology company whose NeuroStar system delivers transcranial magnetic stimulation for major depression, and following its 2024 Merger with Greenbrook TMS it also operates a national network of TMS treatment centers. Shares closed at $2.88 at last closing, up 5.88%.
Its results depend on revenue from its device and treatment-center businesses, its margins, and its progress toward profitability, so it is exposed to Demand for TMS therapy and to its cash runway.
Latest Developments
In its second-quarter 2026 results, Neuronetics reported revenue of about $41.6 million, up roughly 9%, with its Greenbrook treatment-center business contributing the majority, a net loss that narrowed sharply to about $3.4 million, a first positive adjusted EBITDA of around $0.3 million, and gross margin expanding to about 51%, while cash stood at roughly $25 million against guided negative cash flow for the year. Investors should confirm the latest revenue by business, the net loss and adjusted EBITDA, and the cash position and burn directly from SEC filings, recognizing that the turnaround is real but the cash runway is tight.
Financial and Business Position
As a turnaround-oriented medtech, Neuronetics' financial position is defined by its growing revenue, its narrowing losses and first positive adjusted EBITDA, and its limited cash. Investors should focus on revenue by business, the net loss and adjusted EBITDA, and the cash position and burn.
Stock-Market Context
STIM shares closed at $2.88 at last closing, up 5.88%, keeping the stock in penny territory. The stock trades on its turnaround and its path to profitability rather than on established earnings, and the narrowing losses are encouraging even as the tight cash runway remains a genuine risk.
What Investors Should Watch
Watch revenue by business, the net loss and adjusted EBITDA, gross margin, the cash position and burn, and guidance. Continued revenue growth combined with sustained positive adjusted EBITDA and adequate funding would be the clearest signs of a positive surprise, while a tight cash runway or dilution needs would be the principal risks.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...